Quarterly Report · 10-Q
Armata Pharmaceuticals, Inc.
ARMPNYSE_AMERICANEQUITYCurrent
Quarterly Report
Company context
Armata is a late clinical-stage biotechnology company focused on the development of high-purity and potency, pathogen-specific bacteriophage therapeutics for the treatment of antibiotic-resistant and difficult-to-treat bacterial infections using its proprietary bacteriophage-based technology. Armata is developing and advancing a broad pipeline of natural and synthetic phage candidates, including clinical candidates for Pseudomonas aeruginosa, Staphylococcus aureus, and other important pathogens. Armata is committed to advancing phage therapy with drug development expertise that spans bench to clinic, including in-house phage-specific current Good Manufacturing Practices (“cGMP”) manufacturing to support full commercialization.
Current securities
Historical securities (1)
Document unavailable
This filing is not currently available in the archive. Read it on SEC EDGAR ↗